ALK

Biomarkers

ALK is involved in the following curated biomarkers.

Name	Biomarker type	Propositions	Statements
Wild type ALK	Wild type	37	64
v::ALK	Rearrangement	10	25

Therapeutic response

Precision oncology relationships for therapeutic response involving this gene.

Organization(s)	Biomarker(s)	Cancer type	Therapy(ies)
FDA (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab, Bevacizumab, Carboplatin, Paclitaxel
FDA (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab, Carboplatin, Paclitaxel
FDA (1)	Wild type ALK, Wild type EGFR, Wild type ROS1	Non-Small Cell Lung Cancer	Carboplatin, Cemiplimab, Pemetrexed
FDA (1)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR, dMMR	Non-Small Cell Lung Cancer	Cemiplimab
EMA (1) FDA (2)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Pemetrexed, Tremelimumab
EMA (1) FDA (2)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Durvalumab, Pemetrexed, Tremelimumab
EMA (1) FDA (2)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Gemcitabine, Tremelimumab
EMA (1) FDA (2)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Durvalumab, Gemcitabine, Tremelimumab
EMA (1) FDA (2)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Nab-paclitaxel, Tremelimumab
FDA (1)	PD-L1 >= 1%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Ipilimumab, Nivolumab
EMA (2) FDA (2)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Ipilimumab, Nivolumab, Pemetrexed
EMA (2) FDA (2)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Ipilimumab, Nivolumab, Pemetrexed
EMA (2) FDA (2)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Ipilimumab, Nivolumab, Paclitaxel
FDA (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Nivolumab, Paclitaxel
EMA (1) FDA (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Pembrolizumab, Pemetrexed
EMA (1) FDA (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Pembrolizumab, Pemetrexed
FDA (1)	PD-L1 >= 1%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Pembrolizumab
EMA (1) FDA (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Paclitaxel
EMA (1) FDA (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Durvalumab, Gemcitabine
EMA (1) FDA (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Durvalumab, Pemetrexed
EMA (1) FDA (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Pemetrexed
FDA (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Nivolumab, Pemetrexed
FDA (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Gemcitabine, Nivolumab
EMA (2)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Durvalumab, Tremelimumab
EMA (1)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Pembrolizumab
EMA (1)	CD274 amplification, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Pembrolizumab
EMA (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Gemcitabine, Pembrolizumab
EMA (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Gemcitabine, Pembrolizumab
EMA (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Paclitaxel, Pembrolizumab
EMA (1)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR, Wild type ROS1	Non-Small Cell Lung Cancer	Cemiplimab
EMA (1)	PD-L1 >= 1%, Wild type ALK, Wild type EGFR, Wild type ROS1	Non-Small Cell Lung Cancer	Carboplatin, Cemiplimab, Pemetrexed
EMA (2)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab
EMA (1)	Wild type ALK	Non-Small Cell Lung Cancer	Atezolizumab, Carboplatin, Nab-paclitaxel
EMA (1)	Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab, Carboplatin, Nab-paclitaxel
EMA (1)	PD-L1 >= 10% TIIC, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab
EMA (1)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Carboplatin, Pemetrexed, Tislelizumab
EMA (1)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Cisplatin, Pemetrexed, Tislelizumab
EMA (3) FDA (2)	v::ALK	Non-Small Cell Lung Cancer	Alectinib
EMA (1) FDA (1)	v::ALK	Non-Small Cell Lung Cancer	Atezolizumab
EMA (2) FDA (1)	v::ALK	Non-Small Cell Lung Cancer	Brigatinib
EMA (2) FDA (1)	v::ALK	Non-Small Cell Lung Cancer	Ceritinib
EMA (2) FDA (1)	v::ALK	Non-Small Cell Lung Cancer	Crizotinib
EMA (1) FDA (1)	v::ALK	Anaplastic Large Cell Lymphoma	Crizotinib
EMA (1) FDA (1)	v::ALK	Inflammatory Myofibroblastic Tumor	Crizotinib
EMA (2) FDA (1)	v::ALK	Non-Small Cell Lung Cancer	Lorlatinib
FDA (1)	v::ALK	Non-Small Cell Lung Cancer	Ensartinib
EMA (1)	v::ALK	Non-Small Cell Lung Cancer	Atezolizumab, Bevacizumab, Carboplatin, Paclitaxel